Recent patents on therapeutic activities of xanthohumol: a prenylated chalconoid from hops (Humulus lupulus L.)

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Haseleu G, Intelmann D, Hofmann T. Structure determination and sensory evaluation of novel bitter compounds formed from β-acids of Hop (Humulus lupulus L.) upon wort boiling. Food Chem. 116, 71–81 (2009).
  CASGoogle Scholar
• 2. Ocvirk M, Ogrinc N, Kosir IJ. Determination of the geographical and botanical origin of hops (Humulus lupulus L.) using stable isotopes of C, N, and S. J. Agri. Food Chem. 66(8), 2021–2026 (2018).
  Medline CASGoogle Scholar
• 3. Intelmann D, Kummerlowe G, Haseleu G et al. Structures of storage-induced transformation products of the beer’s bitter principles, revealed by sophisticated NMR spectroscopic and LC-MS techniques. Chem. Eur. J. 15, 13047–13058 (2009).
  Medline CASGoogle Scholar
• 4. Eyres G, Dufour JP. Hop essential oil: analysis, chemical composition and odor characteristics. Beer Health Dis. Prevent. 239–254 (2009).
  Google Scholar
• 5. Hieronymus S. For the Love of Hops: The Practical Guide to Aroma, Bitterness and the Culture of Hops. Brewers Publications, CA, USA (2012).
  Google Scholar
• 6. Flythe MD, Kagan IA, Wang Y et al. Hops (Humulus lupulus L.) bitter acids: modulation of rumen fermentation and potential as an alternative growth promoter. Front. Vet. Sci. 4, 131 (2017).
  MedlineGoogle Scholar
• 7. Dresel M, Vogt C, Dunkel A et al. The bitter chemodiversity of hops (Humulus lupulus L.). J. Agri. Food Chem. 4(41), 7789–7799 (2016). •• Highlights the chemistry of xanthohumol (XN) and its derivatives.
  Google Scholar
• 8. Austin MB, Noel JP. The chalcone synthase superfamily of type III polyketide synthases. Nat. Prod. Rep. 20, 79–110 (2003).
  Medline CASGoogle Scholar
• 9. Abe I, Morita H. Cheminform abstract: structure and function of the chalcone synthase superfamily of plant type III polyketide synthases. Nat. Prod. Rep. 27(6), 809–838 (2010).
  Medline CASGoogle Scholar
• 10. Frolich S, Schubert C, Bienzle U et al. In vitro antiplasmodial activity of prenylated chalcone derivatives of hops (Humulus lupulus) and their interaction with haemin. J. Antimicrob. Chemother. 55(6), 883–887 (2005).
  MedlineGoogle Scholar
• 11. Possemiers S, Verstraete W, De Wiele TV. Estrogenicity of beer: the role of intestinal bacteria in the activation of the beer flavonoid isoxanthohumol. Beer Health Dis. Prevent. 523–539 (2009).
  Google Scholar
• 12. Proestos C, Komaitis M. Antioxidant capacity of hops. Beer Health Dis. Prevent. 467–474 (2009).
  Google Scholar
• 13. Deeb D, Gao X, Jiang H et al. Growth inhibitory and apoptosis-inducing effects of xanthohumol, a prenylated chalone present in hops, in human prostate cancer cells. Anticancer Res. 30, 3333–3339 (2010).
  Medline CASGoogle Scholar
• 14. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145, 1215–1229 (2013).
  Medline CASGoogle Scholar
• 15. Jiang CH, Sun TL, Xiang DX et al. Anticancer activity and mechanism of xanthohumol: a prenylated flavonoid from hops (Humulus lupulus L.). Front. Pharmacol. 9, 530 (2018). • Provides information on mechanism of action of XN.
  MedlineGoogle Scholar
• 16. Reitman ZJ, Winkler F, Elia AEH. New directions in the treatment of glioblastoma. Semin. Neurol. 38, 50–61 (2018).
  MedlineGoogle Scholar
• 17. Zanoli P, Zavatti M. Pharmacognostic and pharmacological profile of Humulus lupulus L. J. Ethnopharmacol. 116(3), 383–396 (2008).
  Medline CASGoogle Scholar
• 18. Zanoli P, Zavatti M. Neuropharmacological activity of Humulus lupulus L. Beer Health Dis. Prevent. 549–556 (2009).
  Google Scholar
• 19. Aronson JK. Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (16th Edition). Aronson JK (Ed.). Elsevier Science, USA, 7674 (2015).
  Google Scholar
• 20. Bartmańska A, Wałecka-Zacharska E, Tronina T et al. Antimicrobial properties of spent hops extracts, flavonoids isolated therefrom, and their derivatives. Molecules 23, 2059 (2018).
  Google Scholar
• 21. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health. Phytochemistry 65(10), 1317–1330 (2004). •• Highlights the various therapeutic activities of XN.
  Medline CASGoogle Scholar
• 22. Lupinacci E, Meijerink J, Vincken JP et al. Xanthohumol from hop (Humulus lupulus L.) is an efficient inhibitor of monocyte chemoattractant protein-1 and tumor necrosis factor-α release in LPS-stimulated RAW 264.7 mouse macrophages and U937 human monocytes. J. Agri. Food Chem. 57(16), 7274–7281 (2009).
  Medline CASGoogle Scholar
• 23. Lee YM, Hsieh KH, Lu WJ et al. Xanthohumol, a prenylated flavonoid from hops (Humulus lupulus), prevents platelet activation in human platelets. Evid. Based Complement. Alternat. Med. 2, 10 (2012).
  Google Scholar
• 24. Yasukawa K, Takeuchi M, Takido M. Humulon, a bitter in the hop, inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Oncology 52(2), 156–158 (1995).
  Medline CASGoogle Scholar
• 25. Wesolowska O, Gasiorowska J, Petrus J et al. Interaction of prenylated chalcones and flavanones from common hop with phosphatidylcholine model membranes. Biochem. Biophys. Acta 1838, 173–184 (2014).
  Medline CASGoogle Scholar
• 26. Langezaal CR, Chandra A, Scheffer JJ. Antimicrobial screening of essential oils and extracts of some Humulus lupulus L. cultivars. Pharm. Weekbl. Sci. 14(6), 353–356 (1992).
  Medline CASGoogle Scholar
• 27. Simpson WJ, Smith AR. Factors affecting antibacterial activity of hop compounds and their derivatives. J. Appl. Bacteriol. 72(4), 327–334 (1992).
  Medline CASGoogle Scholar
• 28. Sheu JR, Lee CR, Lin C et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. J. Thromb. Haemost. 83(5), 777–784 (2000).
  CASGoogle Scholar
• 29. Stevens JF, Miranda CL, Frei B et al. Inhibition of peroxynitrite-mediated LDL oxidation by prenylated flavonoids: the alpha,beta-unsaturated keto functionality of 2′-hydroxychalcones as a novel antioxidant pharmacophore. Chem. Res. Toxicol. 16(10), 1277–1286 (2003).
  Medline CASGoogle Scholar
• 30. Schempp H, Vogel S, Hückelhoven R et al. Re-evaluation of superoxide scavenging capacity of xanthohumol. Free Radic. Res. 44, 1435–1444 (2010).
  Medline CASGoogle Scholar
• 31. Hirata H, Yimin Segawa S et al. Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice. PLoS ONE 7, e49415 (2012).
  Medline CASGoogle Scholar
• 32. Henderson MC, Miranda CL, Stevens JF et al. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica 30(3), 235–251 (2000).
  Medline CASGoogle Scholar
• 33. Mannering GJ, Shoeman JA, Shoeman DW. Effects of colupulone, a component of hops and brewers yeast, and chromium on glucose tolerance and hepatic cytochrome P450 in nondiabetic and spontaneously diabetic mice. Biochem. Biophys. Res. Commun. 200(3), 1455–1462 (1994).
  Medline CASGoogle Scholar
• 34. Mannering GJ, Shoeman JA. Murine cytochrome P4503A is induced by 2-methyl-3-buten-2-ol, 3-methyl- 1-pentyn-3-ol (meparfynol), and tert-amyl alcohol. Xenobiotica 26(5), 487–493 (1996).
  Medline CASGoogle Scholar
• 35. Guo J, Nikolic D, Chadwick LR et al. Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (Humulus lupulus L.). Drug Metab. Dispos. 34, 1152–1159 (2006).
  Medline CASGoogle Scholar
• 36. Miranda CL, Yang YH, Henderson MC et al. Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline, mediated by cDNA-expressed human CYP1A2. Drug Metab. Dispos. 28(11), 1297–1302 (2000).
  Medline CASGoogle Scholar
• 37. Miura Y, Hosono M, Oyamada C et al. Dietary isohumulones, the bitter components of beer, raise plasma HDL cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARa activations in C57BL/6 mice. Br. J. Nutr. 93, 559–567 (2005).
  Medline CASGoogle Scholar
• 38. Hänsel R, Wohlfart R, Coper H. Sedative-hypnotic compounds in the exhalation of hops, II. Z. Naturforsch. 35(11-12), 1096–1097 (1980).
  Medline CASGoogle Scholar
• 39. Park SH, Sim YB, Kang YJ et al. Hop extract produces antinociception by acting on opioid system in mice. Korean J. Physiol. Pharmacol. 16(3), 187–192 (2012).
  MedlineGoogle Scholar
• 40. Hänsel R, Wohlfart R, Schmidt H. The sedative-hypnotic principle of hops. 3. Communication: contents of 2-methyl-3-butene-2-ol in hops and hop preparations. Planta Med. 45, 224–228 (1982).
  Medline CASGoogle Scholar
• 41. De Keukeleire J, Ooms G, Heyerick A et al. Formation and accumulation of α-acids, β-acids, desmethylxanthohumol, and xanthohumol during flowering of hops (Humulus lupulus L.). J. Agri. Food Chem. 16, 4436–4441 (2003).
  Google Scholar
• 42. De Keukeleire J, Janssens I, Heyerick A et al. Relevance of organic farming and effect of climatological conditions on the formation of α-acids, β-acids, desmethylxanthohumol, and xanthohumol in hop (Humulus lupulus L.). J. Agr. Food Chem. 55, 61–66 (2007).
  MedlineGoogle Scholar
• 43. Zhang X, Li X, Liu N et al. The anticonvulsant effects of baldrinal on pilocarpine-induced convulsion in adult male mice. Molecules 24(8), 1617 (2019).
  CASGoogle Scholar
• 44. Brodziak-Jarosz L, Fujikawa Y, Pastor-Flores D et al. A click chemistry approach identifies target proteins of xanthohumol. Mol. Nutr. Food Res. 60, 737–748 (2016).
  Medline CASGoogle Scholar
• 45. Magalhaes PJ, Carvalho DO, Cruz JM et al. Fundamentals and health benefits of xanthohumol, a natural product derived from hops and beer. Nat. Prod. Commun. 4, 591–610 (2009). • Discusses the various health benefits of XN.
  Medline CASGoogle Scholar
• 46. Nuti E, Bassani B, Camodeca C et al. Synthesis and antiangiogenic activity study of new hop chalcone xanthohumol analogues. Eur. J. Med. Chem. 138, 890–899 (2017).
  Medline CASGoogle Scholar
• 47. Biendl M, Pinzl C. Hops and health. In: Effects – Efficacy of Individual Hop Components. Biendl MPinzl C (Eds). German Hop Museum, Wolnzach, Germany, 49–76 (2008).
  Google Scholar
• 48. Yajima H, Ikeshima E, Shiraki M et al. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. J. Biol. Chem. 279(32), 33456–33462 (2004).
  Medline CASGoogle Scholar
• 49. Chadwick LR, Nikolic D, Burdette JE et al. Estrogens and congeners from spent hops (Humulus lupulus). J. Nat. Prod. 67(12), 2024–2032 (2004).
  Medline CASGoogle Scholar
• 50. Chadwick LR, Pauli GF. Farnsworth. The pharmacognosy of Humulus lupulus L. (hops) with an emphasis on estrogenic properties. Phytomedicine 13(1-2), 119–131 (2006).
  Medline CASGoogle Scholar
• 51. van Breemen RB, Yuan Y, Banuvar S et al. Pharmacokinetics of prenylated hop phenols in women following oral administration of a standardized extract of hops. Mol. Nutr. Food Res. 58, 1962–1969 (2014).
  Medline CASGoogle Scholar
• 52. Liu J, Burdette JE, Xu H et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J. Agri. Food Chem. 49(5), 2472–2479 (2001).
  Medline CASGoogle Scholar
• 53. Logan IE, Miranda CL, Lowry MB et al. Antiproliferative and cytotoxic activity of xanthohumol and its non-estrogenic derivatives in colon and hepatocellular carcinoma cell lines. Int. J. Mol. Sci. 20, 1203 (2019).
  CASGoogle Scholar
• 54. Possemiers S, Bolca S, Grootaert C et al. The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro and in the human intestine. J. Nutr. 136(7), 1862–1867 (2006).
  Medline CASGoogle Scholar
• 55. Possemiers S, Rabot S, Espin JC et al. Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine. J. Nutr. 138, 1310–1316 (2008).
  Medline CASGoogle Scholar
• 56. Stulikova K, Karabin M, Nespor J et al. Therapeutic perspectives of 8-prenylnaringenin, a potent phytoestrogen from hops. Molecules 23(3), 660 (2018).
  Google Scholar
• 57. Paraiso IL, Plagmann LS, Yang L et al. Reductive metabolism of xanthohumol and 8-prenylnaringenin by the intestinal bacterium Eubacterium ramulus. Mol. Nutr. Food Res. 63, e1800923 (2019).
  MedlineGoogle Scholar
• 58. Franco L, Sanchez C, Bravo R et al. The sedative effects of hops (Humulus lupulus), a component of beer, on the activity/rest rhythm. Acta Physiol. Hung. 99(2), 133–139 (2012).
  Medline CASGoogle Scholar
• 59. Vonderheid-Guth B, Todorova A, Brattstrom A et al. Pharmacodynamic effects of valerian and hops extract combination (Ze 91019) on the quantitative-topographical EEG in healthy volunteers. Eur. J. Med. Res. 5(4), 139–144 (2000).
  Medline CASGoogle Scholar
• 60. Liu M, Hansen PE, Wang G et al. Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus). Molecules 20, 754–779 (2015).
  MedlineGoogle Scholar
• 61. Lecce G, Meduri G, Ancelin M et al. Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J. Clin. Endocrinol. Metab. 86, 1379–1386 (2001).
  Medline CASGoogle Scholar
• 62. Schellenberg R, Sauer S, Abourashed EA. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. Planta Med. 70(7), 594–597 (2004).
  Medline CASGoogle Scholar
• 63. Schiller H, Forster A, Vonhoff C et al. Sedating effects of Humulus lupulus L. extracts. Phytomedicine 13(8), 535–541 (2006).
  Medline CASGoogle Scholar
• 64. Dimpfel W, Pischel I, Lehnfeld R. Effects of lozenge containing lavender oil, extracts from hops, lemon balm and oat on electrical brain activity of volunteers. Eur. J. Med. Res. 9(9), 423–431 (2004).
  Medline CASGoogle Scholar
• 65. Wohlfart R, Wurm G, Hansel R et al. Detection of sedative-hypnotic active ingredients in hops. 5. Degradation of bitter acids to 2-methyl-3-buten-2-ol, a hop constituent with sedative-hypnotic activity. Arch. Pharm. (Weinheim) 316(2), 132–137 (1983).
  Medline CASGoogle Scholar
• 66. Legette L, Ma L, Reed RL et al. Pharmacokinetics of xanthohumol and metabolites in rats after oral and intravenous administration. Mol. Nutr. Food Res. 56, 466–474 (2012).
  Medline CASGoogle Scholar
• 67. Kac J, Plazar J, Mlinarič A et al. Antimutagenicity of hops (Humulus lupulus L.): bioassay-directed fractionation and isolation of xanthohumol. Phytomedicine 15, 216–220 (2008).
  Medline CASGoogle Scholar
• 68. Salehi B, Upadhyay S, Erdogan OI et al. Therapeutic potential of α- and β-pinene: a miracle gift of nature. Biomolecules 9, 738 (2019).
  CASGoogle Scholar
• 69. Aggarwal V, Kashyap D, Sak K et al. Molecular mechanisms of action of tocotrienols in cancer: recent trends and advancements. Int. J. Mol. Sci. 20(3), 656 (2019).
  CASGoogle Scholar
• 70. Kashyap D, Sharma A, Sak K et al. Fisetin: a bioactive phytochemical with potential for cancer prevention and pharmacotherapy. Life Sci. 194, 75–87 (2018).
  Medline CASGoogle Scholar
• 71. Tuli HS, Tuorkey MJ, Thakral F et al. Molecular mechanisms of action of genistein in cancer: recent advances. Front. Pharmacol. 10, 1336 (2019).
  Medline CASGoogle Scholar
• 72. Kashyap D, Sharma A, Tuli HS et al. Molecular targets of celastrol in cancer: recent trends and advancements. Crit. Rev. Oncol. Hematol. 128, 70–81 (2018).
  MedlineGoogle Scholar
• 73. Sharma A, Ghani A, Sak K et al. Probing into therapeutic anti-cancer potential of apigenin: recent trends and future directions. Recent Pat. Inflamm. Allergy Drug Discov. 13(2), 124–133 (2019).
  Medline CASGoogle Scholar
• 74. Chaudhary A, Jaswal VS, Choudhary S et al. Ferulic acid: a promising therapeutic phytochemical and recent patents advances. Recent Pat. Inflamm. Allergy Drug Discov. 13(2), 115–123 (2019).
  Medline CASGoogle Scholar
• 75. Yadav P, Jaiswal V, Sharma A et al. Celastrol as a pentacyclic triterpenoid with chemopreventive properties. Pharm. Pat. Anal. 7(4), 155–167 (2018).
  CASGoogle Scholar
• 76. Tuli HS, Kashyap D, Sharma AK, Sandhu SS. Molecular aspects of melatonin (MLT)-mediated therapeutic effects. Life Sci. 135, 147–157 (2015).
  Medline CASGoogle Scholar
• 77. Kashyap D, Tuli HS, Sharma AK. Ursolic acid (UA): a metabolite with promising therapeutic potential. Life Sci. 146, 201–213 (2016).
  Medline CASGoogle Scholar
• 78. Lee IS, Lim J, Gal J et al. Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells. Neurochem. Int. 58(2), 153–160 (2011).
  Medline CASGoogle Scholar
• 79. Weiskirchen R, Mahli A, Weiskirchen S et al. The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels. Front. Physiol. 6, 140 (2015).
  MedlineGoogle Scholar
• 80. Luzak B, Kassassir H, Rój E, Stanczyk L, Watala C, Golanski J. Xanthohumol from hop cones (Humulus lupulus L.) prevents ADP-induced platelet reactivity. Arch. Physiol. Biochem. 123, 54–60 (2017).
  Medline CASGoogle Scholar
• 81. Liu W, Li W, Liu H, Yu X. Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis. Int. J. Biol. Sci. 15, 2497–2508 (2019)
  Medline CASGoogle Scholar
• 82. Mishra AP, Salehi B, Sharifi-Rad M et al. . Programmed cell death, from a cancer perspective: an overview. Mol. Diagn. Ther. 22(3), 281–295 (2018).
  Medline CASGoogle Scholar
• 83. Sławińska-Brych A, Zdzisińska B, Czerwonka A et al. Xanthohumol exhibits anti-myeloma activity in vitro through inhibition of cell proliferation, induction of apoptosis via the ERK and JNK-dependent mechanism, and suppression of sIL-6R and VEGF production. Biochim. Biophys. Acta 1863(11), 129408 (2019).
  CASGoogle Scholar
• 84. Kang Y, Park MA, Heo SW et al. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. Biochim. Biophys. Acta 1830(3), 2638–2648 (2013).
  Medline CASGoogle Scholar
• 85. Saito K, Matsuo Y, Imafuji H et al. Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer. Cancer Sci. 109(1), 132–140 (2018).
  Medline CASGoogle Scholar
• 86. Viola K, Kopf S, Rarova L et al. Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Arch. Toxicol. 87(7), 1301–1312 (2013).
  Medline CASGoogle Scholar
• 87. Lee IS, Lim J, Gal J et al. Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells. Neurochem. Int. 58(2), 153–160 (2011).
  Medline CASGoogle Scholar
• 88. Gupta H, Kumar S, Roy SK, Gaud RS. Patent protection strategies. J. Pharm. Bioall. Sci. 2, 2–7 (2010)
  MedlineGoogle Scholar
• 89. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 151–185 (2003). •• Highlights importance of patents in pharmaceutical world.
  MedlineGoogle Scholar
• 90. Grubb PW. Patents for chemicals, pharmaceuticals and biotechnology: Fundamentals of Global Law, Practice and Strategy (2nd Edition). Oxford University Press, London, UK (1999).
  Google Scholar
• 91. Gersten DM. The quest for market exclusivity in biotechnology: navigating the patent minefield. NeuroRx 2(4), 572–578 (2005).
  MedlineGoogle Scholar
• 92. Miranda CL, Stevens JF, Ivanov V et al. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J. Agri. Food Chem. 48(9), 3876–3884 (2000).
  Medline CASGoogle Scholar
• 93. Gerhäuser C. Broad spectrum anti-infective potential of xanthohumol from hop (Humulus lupulus L.) in comparison with activities of other hop constituents and xanthohumol metabolites. Mol. Nutr. Food Res. 49(9), 827–831 (2005).
  MedlineGoogle Scholar
• 94. Legette LL, Luna AY, Reed RL et al. Xanthohumol lowers body weight and fasting plasma glucose in obese male Zucker fa/fa rats. Phytochemistry 91, 236–241 (2013).
  Medline CASGoogle Scholar
• 95. Dorn C, Massinger S, Wuzik A et al. Xanthohumol suppresses inflammatory response to warm ischemia-reperfusion induced liver injury. Exp. Mol. Pathol. 94(1), 10–16 (2013).
  Medline CASGoogle Scholar
• 96. Erkkola R, Vervarcke S, Vansteelandt S et al. A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine 17(6), 389–396 (2010).
  Medline CASGoogle Scholar
• 97. Ambrož M, Lněničková K, Matoušková P et al. Antiproliferative effects of hop-derived prenylflavonoids and their influence on the efficacy of oxaliplatine, 5-fluorouracil and irinotecan in human colorectal C cells. Nutrients 11(4), 879 (2019).
  CASGoogle Scholar
• 98. Gerhäuser C. Beer constituents as potential cancer chemopreventive agents. Eur. J. Cancer 41(13), 1941–1954 (2005).
  MedlineGoogle Scholar
• 99. Jia Q, Jiao P, Yimam M et al. : US20200206292A1 (2020).
  Google Scholar
• 100. Brownell LA, Hong MCMF, Hyun EJ et al. : AU2019201188A1 (2019).
  Google Scholar
• 101. Brownell LA, Chu M, Hong MF et al. : AU2020201457A1 (2020).
  Google Scholar
• 102. Xiaolan W, Chen Y, Ming L: CN110754664A (2019).
  Google Scholar
• 103. Yuhua T: 111195334A (2020).
  Google Scholar
• 104. Wang L, Zhang J: 111281851A (2019).
  Google Scholar
• 105. Yamaguchi N, Satoh-Yamaguchi K, Ono M. In vitro evaluation of antibacterial, anticollagenase, and antioxidant activities of hop components (Humulus lupulus) addressing acne vulgaris. Phytomedicine 16, 369–376 (2009).
  Medline CASGoogle Scholar
• 106. Fukizawa S, Takagi R: WO2020116382A1 (2019).
  Google Scholar
• 107. Fukizawa S: WO2020116381A1 (2019).
  Google Scholar
• 108. Fukizawa S, Risa Y, Takagi et al. : WO2020116383A1 (2019).
  Google Scholar
• 109. Adnan MMM, Polisetti DR, Kassis JN et al. : US20200148673A1 (2020).
  Google Scholar
• 110. Werner-Backachim W, Wunderrich Z: JP2020090501A (2019).
  Google Scholar
• 111. Hamid R, Noel S, Maria N et al. : US20200120909A1 (2019).
  Google Scholar
• 112. Young CL, Su YY, Su HY et al. : WO2020106084A1 (2019).
  Google Scholar
• 113. Marcel B, Thérèse D: WO2020094767A1 (2019).
  Google Scholar
• 114. Ingo L, Johannes G, Vera P et al. : WO2020084105A2 (2019).
  Google Scholar
• 115. Ivan G: WO2020086820A1 (2019).
  Google Scholar
• 116. Alain D, Baron, Nigel RA, Beeley et al. : AU2019253780A1 (2019).
  Google Scholar
• 117. Durham L: JP2020059711A (2019).
  Google Scholar
• 118. Jiang P, Liu X, Bai J et al. : 110613706A (2019).
  Google Scholar
• 119. Akihiro TM, Yuko T, Yoshinaga et al. : WO2020067453A1 (2019).
  Google Scholar
• 120. Chen Z, Sang F, Kong L et al. : 110590520A (2019).
  Google Scholar
• 121. Otis CA: US20200016131A1 (2019).
  Google Scholar
• 122. Yi R: US20200165608A1 (2019).
  Google Scholar
• 123. Kenwaljit SB: WO2020061584A1 (2019).
  Google Scholar
• 124. Bjoern CK: US20190381023A1 (2019).
  Google Scholar
• 125. Nikhat C, Jennifer JR: WO2020033796A1 (2019).
  Google Scholar
• 126. Shinya MF, Kenichi Y, Wakabayashi: WO2020031957A1 (2019).
  Google Scholar
• 127. Shinya FY, Nonaka M, Yamashita: WO2020031952A1 (2019).
  Google Scholar
• 128. Junki Y, Kusotaro T: WO2020031961A1 (2019).
  Google Scholar
• 129. Cong YJ, Chunpeng Z, Xueqiang Zh et al. : 110251436A (2019).
  Google Scholar
• 130. Peter S, Talyn S, Paul D et al. : WO2020027665A1 (2019).
  Google Scholar
• 131. Junmo Y, Park Y, Kim Y et al. : KR102074614B1 (2019).
  Google Scholar
• 132. Geoffrey A, Von M, Jared S et al. : US20200093851A1 (2019).
  Google Scholar
• 133. Jeffrey ES: WO2019210073A1 (2019).
  Google Scholar
• 134. Kim JSS, Do K: KR102015854B1 (2019).
  Google Scholar
• 135. Rio MJD, Julia CW, Lopez-Rios L et al. : US20190216872A1 (2019).
  Google Scholar
• 136. Gokaraju GR, Gokaraju VKRR, Golakoti RRGT et al. : WO2019171397A1 (2019).
  Google Scholar
• 137. Baillie RF, Davis PF, Tinte I, Tan ST: US20200041521A1 (2019).
  Google Scholar
• 138. Yongbo Z, Ping L, Xiaoshuang L: 109589331A (2019).
  Google Scholar
• 139. Behnam D: WO2020011402A1 (2019).
  Google Scholar